Loading…
Loading…
REGN · NASDAQ · Healthcare
“While most investors chase the next miracle drug, Regeneron's real moat lies in their platform that manufactures miracles with the reliability of a pharmaceutical assembly line.”
— In the voice of Munger
Compute the compound annual growth rate for any investment period. The true annualized return that accounts for compounding.
Market Cap
$78.21B
P/E Ratio
17.36
Forward P/E
—
EPS
$43.07
PEG Ratio
-4.94
Book Value
$298.82
Dividend Yield
0.48%
Profit Margin
31.41%
ROE
14.41%
Use the interactive cagr calculator with pre-loaded data for Regeneron Pharmaceuticals Inc. Adjust discount rates, growth assumptions, and projection horizons to model different scenarios.
Pre-loaded inputs for REGN: